BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/22/2022 8:49:02 AM | Browse: 403 | Download: 776
 |
Received |
|
2021-04-03 23:33 |
|
Peer-Review Started |
|
2021-04-03 23:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-06 01:26 |
|
Revised |
|
2021-09-04 06:03 |
|
Second Decision |
|
2022-04-02 02:09 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-04-04 06:10 |
|
Articles in Press |
|
2022-04-04 06:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-04-01 03:48 |
|
Typeset the Manuscript |
|
2022-04-06 10:21 |
|
Publish the Manuscript Online |
|
2022-04-22 08:49 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Tsunami of immunotherapy reaches mesothelioma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xabier Mielgo-Rubio, Ana Cardeña Gutiérrez, Verónica Sotelo Peña, Maria Virginia Sánchez Becerra, Andrea María González López, Adriana Rosero, Juan Carlos Trujillo-Reyes and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xabier Mielgo-Rubio, MD, Doctor, Doctor, Staff Physician, Medical Oncology, Hospital Universitario Fundación Alcorcón, Budapest 1, Alcorcón 28922, Madrid, Spain. xmielgo@hotmail.com |
| Key Words |
Mesothelioma; Malignant pleural mesothelioma; Immunotherapy; Immune checkpoint inhibitors; Cytotoxic T-lymphocyte–associated antigen 4; Programmed cell death protein 1; Nivolumab; Ipilimumab; Immunotherapy combo; CheckMate 743; CONFIRM |
| Core Tip |
Malignant pleural mesothelioma (MPM) is the most common type of malignant mesothelioma and is associated with a poor prognosis. The treatment options for advanced MPM were limited until very recently, when the results from two phase III trials showed improved survival in patients treated with immunotherapy. In the first trial, CheckMate 743, nivolumab plus ipilimumab as first-line therapy achieved better overall survival than standard chemotherapy, while in the second trial, CONFIRM, nivolumab vs placebo significantly improved overall survival in patients previously treated with chemotherapy. In this article, we discuss recent advances and highlights in the treatment of MPM. |
| Publish Date |
2022-04-22 08:49 |
| Citation |
Mielgo-Rubio X, Cardeña Gutiérrez A, Sotelo Peña V, Sánchez Becerra MV, González López AM, Rosero A, Trujillo-Reyes JC, Couñago F. Tsunami of immunotherapy reaches mesothelioma. World J Clin Oncol 2022; 13(4): 267-275 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i4/267.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i4.267 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
